{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T18:56:03Z","timestamp":1781895363643,"version":"3.54.5"},"reference-count":44,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,21]],"date-time":"2022-01-21T00:00:00Z","timestamp":1642723200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["18K09219"],"award-info":[{"award-number":["18K09219"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["fertstertscience.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["F&S Science"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.xfss.2022.01.005","type":"journal-article","created":{"date-parts":[[2022,1,21]],"date-time":"2022-01-21T12:38:34Z","timestamp":1642768714000},"page":"187-196","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Antitumor effect of the selective hypoxia-inducible factor-1 inhibitors echinomycin and PX-478 on uterine fibroids"],"prefix":"10.1016","volume":"3","author":[{"given":"Linlin","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1116-6885","authenticated-orcid":false,"given":"Hiroshi","family":"Ishikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanruo","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5072-6756","authenticated-orcid":false,"given":"Tatsuya","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7247-2205","authenticated-orcid":false,"given":"Makio","family":"Shozu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xfss.2022.01.005_bib1","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1056\/NEJMra1209993","article-title":"Uterine fibroids","volume":"369","author":"Bulun","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.xfss.2022.01.005_bib2","doi-asserted-by":"crossref","first-page":"4719","DOI":"10.1158\/0008-5472.CAN-07-6339","article-title":"Lack of hypoxic response in uterine leiomyomas despite severe tissue hypoxia","volume":"68","author":"Mayer","year":"2008","journal-title":"Cancer Res"},{"key":"10.1016\/j.xfss.2022.01.005_bib3","doi-asserted-by":"crossref","first-page":"3664","DOI":"10.1172\/JCI67230","article-title":"HIF-1 mediates metabolic responses to intratumoral hypoxia and oncogenic mutations","volume":"123","author":"Semenza","year":"2013","journal-title":"J Clin Invest"},{"key":"10.1016\/j.xfss.2022.01.005_bib4","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1177\/1933719118776793","article-title":"Hypoxia induces hypoxia-inducible factor 1\u03b1 and potential HIF-responsive gene expression in uterine leiomyoma","volume":"26","author":"Ishikawa","year":"2019","journal-title":"Reprod Sci"},{"key":"10.1016\/j.xfss.2022.01.005_bib5","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1056\/NEJMoa2008283","article-title":"Treatment of uterine fibroid symptoms with relugolix combination therapy","volume":"384","author":"Al-Hendy","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.xfss.2022.01.005_bib6","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1056\/NEJMoa1103182","article-title":"Ulipristal acetate versus placebo for fibroid treatment before surgery","volume":"366","author":"Donnez","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.xfss.2022.01.005_bib7","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1007\/s40265-017-0812-3","article-title":"Ulipristal acetate: a review in symptomatic uterine fibroids","volume":"77","author":"Garnock-Jones","year":"2017","journal-title":"Drugs"},{"key":"10.1016\/j.xfss.2022.01.005_bib8","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1111\/bcpt.13631","article-title":"Acute liver failure requiring transplantation: a possible link to ulipristal acetate treatment?","volume":"129","author":"Dinis-Oliveira","year":"2021","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"10.1016\/j.xfss.2022.01.005_bib10","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s11912-019-0752-z","article-title":"HIF inhibitors: status of current clinical development","volume":"21","author":"Fallah","year":"2019","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.xfss.2022.01.005_bib11","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1097\/00000421-199008000-00006","article-title":"Echinomycin (NSC 526417) in advanced ovarian cancer. A phase II trial of the Gynecologic Oncology Group","volume":"13","author":"Muss","year":"1990","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.xfss.2022.01.005_bib12","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1097\/00000421-199312000-00006","article-title":"Echinomycin in recurrent and metastatic endometrial carcinoma. A phase II trial of the Gynecologic Oncology Group","volume":"16","author":"Muss","year":"1993","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.xfss.2022.01.005_bib13","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/BF01275474","article-title":"Echinomycin (NSC 526417) in recurrent and metastatic squamous cell carcinoma of the cervix. A phase II trial of the Gynecologic Oncology Group (GOG)","volume":"10","author":"Muss","year":"1992","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.xfss.2022.01.005_bib14","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1097\/00000421-199006000-00002","article-title":"Echinomycin (NSC 526417) in squamous-cell carcinoma of the cervix. A phase II trial of the Gynecologic Oncology Group","volume":"13","author":"Muss","year":"1990","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.xfss.2022.01.005_bib15","first-page":"1198","article-title":"Inhibition of HIF-1\u03b1 by PX-478 suppresses tumor growth of esophageal squamous cell cancer in\u00a0vitro and in\u00a0vivo","volume":"7","author":"Zhu","year":"2017","journal-title":"Am J Cancer Res"},{"key":"10.1016\/j.xfss.2022.01.005_bib16","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1158\/1535-7163.233.3.3","article-title":"Antitumor activity and pharmacodynamic properties of PX-478, an inhibitor of hypoxia-inducible factor-1alpha","volume":"3","author":"Welsh","year":"2004","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.xfss.2022.01.005_bib17","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1158\/1535-7163.MCT-07-0463","article-title":"Molecular mechanisms for the activity of PX-478, an antitumor inhibitor of the hypoxia-inducible factor-1alpha","volume":"7","author":"Koh","year":"2008","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.xfss.2022.01.005_bib18","doi-asserted-by":"crossref","first-page":"3852","DOI":"10.1210\/endo.141.10.7719","article-title":"In situ estrogen synthesized by aromatase P450 in uterine leiomyoma cells promotes cell growth probably via an autocrine\/intracrine mechanism","volume":"141","author":"Sumitani","year":"2000","journal-title":"Endocrinology"},{"key":"10.1016\/j.xfss.2022.01.005_bib19","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1210\/jcem.87.6.8533","article-title":"Overexpression of aromatase P450 in leiomyoma tissue is driven primarily through promoter I.4 of the aromatase P450 gene (CYP19)","volume":"87","author":"Shozu","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.xfss.2022.01.005_bib20","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1016\/j.fertnstert.2014.01.054","article-title":"Nonobese diabetic\/severe combined immunodeficient murine xenograft model for human uterine leiomyoma","volume":"101","author":"Wang","year":"2014","journal-title":"Fertil Steril"},{"key":"10.1016\/j.xfss.2022.01.005_bib21","doi-asserted-by":"crossref","first-page":"3041","DOI":"10.1245\/s10434-014-4323-0","article-title":"Targeting HIF1\u03b1 peri-operatively increased post-surgery survival in a tongue cancer animal model","volume":"22","author":"Ahn","year":"2015","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.xfss.2022.01.005_bib22","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1111\/j.1582-4934.2009.00876.x","article-title":"Development of HIF-1 inhibitors for cancer therapy","volume":"13","author":"Onnis","year":"2009","journal-title":"J Cell Mol Med"},{"key":"10.1016\/j.xfss.2022.01.005_bib23","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.pharmthera.2016.04.009","article-title":"Therapeutic targeting of hypoxia and hypoxia-inducible factors in cancer","volume":"164","author":"Wigerup","year":"2016","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.xfss.2022.01.005_bib24","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.1093\/humrep\/del220","article-title":"The normal human myometrium has a vascular spatial gradient absent in small fibroids","volume":"21","author":"Aitken","year":"2006","journal-title":"Hum Reprod"},{"key":"10.1016\/j.xfss.2022.01.005_bib25","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1093\/humrep\/deg213","article-title":"Vascular system of intramural leiomyomata revealed by corrosion casting and scanning electron microscopy","volume":"18","author":"Walocha","year":"2003","journal-title":"Hum Reprod"},{"key":"10.1016\/j.xfss.2022.01.005_bib26","doi-asserted-by":"crossref","first-page":"9047","DOI":"10.1158\/0008-5472.CAN-05-1235","article-title":"Echinomycin, a small-molecule inhibitor of hypoxia-inducible factor-1 DNA-binding activity","volume":"65","author":"Kong","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.xfss.2022.01.005_bib27","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/BF00170766","article-title":"Echinomycin: the first bifunctional intercalating agent in clinical trials","volume":"3","author":"Foster","year":"1985","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.xfss.2022.01.005_bib28","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1007\/BF00685088","article-title":"Phase II trial of echinomycin in patients with advanced or recurrent colorectal cancer","volume":"34","author":"Wadler","year":"1994","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.xfss.2022.01.005_bib29","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/BF00176982","article-title":"Phase II study of echinomycin in patients with advanced breast cancer: a report of Cancer and Leukemia Group B protocol 8641","volume":"9","author":"Schilsky","year":"1991","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.xfss.2022.01.005_bib30","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/BF00873239","article-title":"Phase II trial of echinomycin in advanced hormone-resistant prostate cancer. An Illinois Cancer Council study","volume":"12","author":"Shevrin","year":"1994","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.xfss.2022.01.005_bib31","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1007\/s12272-011-1021-3","article-title":"A novel approach to cancer therapy using PX-478 as a HIF-1\u03b1 inhibitor","volume":"34","author":"Lee","year":"2011","journal-title":"Arch Pharm Res"},{"key":"10.1016\/j.xfss.2022.01.005_bib32","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1158\/1535-7163.MCT-08-0981","article-title":"The selective hypoxia inducible factor-1 inhibitor PX-478 provides in\u00a0vivo radiosensitization through tumor stromal effects","volume":"8","author":"Schwartz","year":"2009","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.xfss.2022.01.005_bib33","doi-asserted-by":"crossref","first-page":"2430","DOI":"10.1002\/ijc.23807","article-title":"PX-478, an inhibitor of hypoxia-inducible factor-1alpha, enhances radiosensitivity of prostate carcinoma cells","volume":"123","author":"Palayoor","year":"2008","journal-title":"Int J Cancer"},{"key":"10.1016\/j.xfss.2022.01.005_bib34","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.18632\/oncotarget.2948","article-title":"Inhibition of HIF-1\u03b1 by PX-478 enhances the anti-tumor effect of gemcitabine by inducing immunogenic cell death in pancreatic ductal adenocarcinoma","volume":"6","author":"Zhao","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.xfss.2022.01.005_bib35","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1097\/00004347-200010000-00008","article-title":"Pathologic features of uterine leiomyomas following uterine artery embolization","volume":"19","author":"McCluggage","year":"2000","journal-title":"Int J Gynecol Pathol"},{"key":"10.1016\/j.xfss.2022.01.005_bib36","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/S1051-0443(07)61882-X","article-title":"Fibroid calcification after uterine artery embolization: ultrasonographic appearance and pathology","volume":"12","author":"Nicholson","year":"2001","journal-title":"J Vasc Interv Radiol"},{"key":"10.1016\/j.xfss.2022.01.005_bib37","doi-asserted-by":"crossref","first-page":"323","DOI":"10.3109\/09513590.2015.1121225","article-title":"Effects of the hypoxia-inducible factor-1 inhibitor echinomycin on vascular endothelial growth factor production and apoptosis in human ectopic endometriotic stromal cells","volume":"32","author":"Tsuzuki","year":"2016","journal-title":"Gynecol Endocrinol"},{"key":"10.1016\/j.xfss.2022.01.005_bib38","first-page":"3099","article-title":"Effects of the HIF1 inhibitor, echinomycin, on growth and NOTCH signalling in leukaemia cells","volume":"33","author":"Yonekura","year":"2013","journal-title":"Anticancer Res"},{"key":"10.1016\/j.xfss.2022.01.005_bib39","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.mce.2014.11.023","article-title":"The role of hypoxia and HIF1\u03b1 in the regulation of STAR-mediated steroidogenesis in granulosa cells","volume":"401","author":"Kowalewski","year":"2015","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.xfss.2022.01.005_bib40","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1007\/s12192-015-0575-2","article-title":"Hypoxia-inducible factor-1\u03b1 regulates the expression of L-type voltage-dependent Ca(2+) channels in PC12 cells under hypoxia","volume":"20","author":"Li","year":"2015","journal-title":"Cell Stress Chaperones"},{"key":"10.1016\/j.xfss.2022.01.005_bib41","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1158\/1535-7163.MCT-09-0150","article-title":"Inhibition of hypoxia-inducible factor-1 function enhances the sensitivity of multiple myeloma cells to melphalan","volume":"8","author":"Hu","year":"2009","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.xfss.2022.01.005_bib42","first-page":"2049","article-title":"Effect of perioperative treatment with a hypoxia-inducible factor-1-alpha inhibitor in an orthotopic surgical mouse model of thyroid cancer","volume":"35","author":"Cha","year":"2015","journal-title":"Anticancer Res"},{"key":"10.1016\/j.xfss.2022.01.005_bib43","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.1038\/s41388-020-1201-z","article-title":"Therapeutic targeting of TP53-mutated acute myeloid leukemia by inhibiting HIF-1\u03b1 with echinomycin","volume":"39","author":"Wang","year":"2020","journal-title":"Oncogene"},{"key":"10.1016\/j.xfss.2022.01.005_bib44","article-title":"Liposomal formulation of HIF-1\u03b1 inhibitor echinomycin eliminates established metastases of triple-negative breast cancer","volume":"29","author":"Bailey","year":"2020","journal-title":"Nanomedicine"},{"key":"10.1016\/j.xfss.2022.01.005_bib45","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1097\/JTO.0b013e3181dc211f","article-title":"Treatment with HIF-1alpha antagonist PX-478 inhibits progression and spread of orthotopic human small cell lung cancer and lung adenocarcinoma in mice","volume":"5","author":"Jacoby","year":"2010","journal-title":"J Thorac Oncol"}],"container-title":["F&S Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666335X22000052?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666335X22000052?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T21:07:26Z","timestamp":1762981646000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666335X22000052"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":44,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["S2666335X22000052"],"URL":"https:\/\/doi.org\/10.1016\/j.xfss.2022.01.005","relation":{},"ISSN":["2666-335X"],"issn-type":[{"value":"2666-335X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antitumor effect of the selective hypoxia-inducible factor-1 inhibitors echinomycin and PX-478 on uterine fibroids","name":"articletitle","label":"Article Title"},{"value":"F&S Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xfss.2022.01.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier Inc. on behalf of American Society for Reproductive Medicine.","name":"copyright","label":"Copyright"}]}}